MannKind Corporation (MNKD) 銘柄情報

Come on Mike and Martine

Love U both but if a big buyout's coming (UTHR and Big Pharma splitting up MNKD), let's get our game on and let er rip!

Over a million share buy block today at $6.60. Very Bullish. 

Happy trading. 

Long time Mannkinder here...

Hard to believe with their recent debt reduction, this isn't a major take out targer for Big Pharma...

Time will tell

BUY rating on technicals issued on Friday 

Mannkind, my kind of stock, news out boys

https://finance.yahoo.com/news/mannkind-corporation-announces-exchange-convertible-120000933.html


-T

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-six-month-results-phase-3-inhale-1-pediatric

https://investors.mannkindcorp.com/node/20181/pdf

👍 https://investors.mannkindcorp.com/news-releases/news-release-details/cdsco-approves-afrezzar-insulin-human-inhalation-powder-india

Come on Big Pharma...

You have to realize the untapped potential of techno-sphere as a delivery system

Swoop in amd snatch this company up for $40 + a share (pennies on future dollars for you)

https://investors.mannkindcorp.com/node/20136/html

UBS Global Healthcare Conference
11/12/24 at 1:15 PM EST

MNKD, 10Q 11/7

MNKD, new 52 week high

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2024-third-quarter-financial-results

MNKD anew 52 week high

This company with their Techno Shere delivery system is low hanging fruit that Big Pharma should be all over...

Come on, ruin Mike and Martine's (like both but Mike will make bank and Martine's had her chances to buybout mnkd) perfect party and someone take this out at $40+ a share....

Up and to the right Mannkind looking better than ever. Lets Go!

May Mannkind be taken out at $35 a share but some out of the blue, no one saw it coming, Big Pharma conglomerate...

And hoping it won't screw UTHR up too much but Martine has had her chances here...

Martine & UTHR should “pony up” & purchase Mannkind before an unknown entity moves in & potentially ruins United’s perfect party

30-week results from the Phase 4 INHALE-3 study expand upon the positive 17-week data presented earlier this year at the American Diabetes Association’s 84th Scientific Sessions

Switching to, or remaining on Afrezza allowed twice as many people to get to goal during the extension phase

https://investors.mannkindcorp.com/news-releases/news-release-details/more-adults-type-1-diabetes-achieved-a1c-goal

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-clearance-pmda-initiate-phase-3-clinical

MNKD under $7

Under $5 is a joke . Worth so much more considering its value to diabetics.

https://learnaboutntm.com/

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-launches-educational-website-raise-awareness-ntm-lung

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast.

MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.

https://investors.mannkindcorp.com/news-releases/news-release-details/inhale-3-study-reveals-positive-readout-head-head-comparison

MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix

05/29/24

Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D space
Non-cash deal includes royalty-free iSPERSE™ technology license in exchange for access to MannKind’s Cricket® inhaler
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has agreed to in-license iSPERSE™ technology from Pulmatrix for certain indications in exchange for an out-license of MannKind’s Cricket® inhaler to Pulmatrix for inhaled delivery of dihydroergotamine (DHE) for migraine treatment. The two companies also agreed that Pulmatrix will transfer its Bedford, Mass. R&D facility to MannKind, along with all leasehold improvements, laboratory equipment and other related personal property used in the laboratory in non-cash transaction.

“We are delighted to grow our Boston-area presence as we continue to progress our pipeline efforts, and in particular, our expanding orphan lung programs,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “We have formulated two FDA-approved products utilizing our proven Technosphere® dry powder technology, and this agreement affords us access to another option for future development opportunities.”

“Our Technosphere technology, which is a unique carrier-based, dry powder inhalation platform used in tandem with our proprietary inhaler, provides deep and effective penetration of lung tissue that is well suited for many active ingredients,” said Dr. Burkhard Blank, Executive Vice President, Research & Development and Chief Medical Officer of MannKind Corporation. “However, for some drug candidates, such as Clofazimine, that may require a significantly higher drug payload, the iSPERSE formulation technology may be better suited for developing viable powders.”

The royalty-free licensing structure will allow MannKind to have exclusive use of the iSPERSE technology for clofazimine, NTM, and insulin, and non-exclusive use for endocrine diseases and interstitial lung diseases (ILD) including idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PFF) and other related lung diseases. In exchange, Pulmatrix will receive a royalty-free, exclusive license to MannKind’s single-use Cricket inhalation device for inhaled delivery of DHE in any formulation and non-exclusive use for neurological diseases.

MannKind expects to consolidate its Boston presence by transitioning its Marlborough staff into the newly renovated, fully outfitted R&D facility in Bedford. To maintain continuity of iSPERSE platform knowledge, MannKind plans to hire some members of current Pulmatrix R&D staff.

The agreement is anticipated to close in July 2024.

06/05/24

17-week endpoint results comparing Afrezza® head-to-head with multiple daily injections (MDI) and insulin pumps

INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced that the 17-week endpoint results from the INHALE-3 study will be presented during a 90-minute symposium and livestream on Saturday, June 22, at the American Diabetes Association’s (ADA) 84th Scientific Sessions. The presentation will be delivered by INHALE-3 Study Protocol Chair Dr. Irl B. Hirsh and the investigational team and will be moderated by Jaeb Center founder Dr. Roy W. Beck.

“We are excited for the first read-out of results from the largest post-market clinical trial MannKind has conducted with Afrezza in the last 10 years,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “The results will speak to the common question about Afrezza: ‘How does inhaled insulin fare when compared head-to-head with usual care?’ The full 30-week results of INHALE-3 will be available later this year.”

Title:
The Efficacy and Safety of Inhaled Insulin Used with Insulin Degludec Compared with Automated Insulin Delivery or Multiple Daily Injections in Adults with Type 1 Diabetes
Date: Saturday, June 22, 2024
Times: 8:00-9:30 AM (ET) with topics/presenters to include:

Inhaled Insulin’s History and Study Rationale – Dr. Halis Akturk

Study Methods & Participant Baseline Characteristics – Dr. Yogish Kudva

Study Results I: Comparison of Inhaled Insulin vs. Rapid Acting Analogue Insulin in Users of AID or

MDI During Standardized In-Clinic Meal Challenge –Dr. Ruth S. Weinstock

Study Results II: Primary Efficacy, Safety, and Quality of Life Outcomes – Dr. Carol J. Levy

Study Results III: Effect of Inhaled Insulin-Degludec Compared with AID and in Subgroups According

to Participant Characteristics – Dr. Grazia Aleppo

Critique of Study Design and Results – by Dr. Irl B. Hirsch

Use of Afrezza in Clinical Practice – by Dr. Thomas Blevins

Question and Answer Session – Moderated by Dr. Roy W. Beck
Location: W320 Chapin Theatre at the Orange County Convention Center (+livestream)
Livestream:
Please refer to https://professional.diabetes.org/scientific-sessions for access details

MannKind will host booth# 1307 in the Exhibit Hall throughout the Scientific Sessions as well. Members of MannKind’s Clinical Education Team will be available for scientific exchange in the medical section of the booth.

https://investors.mannkindcorp.com/news-releases/news-release-details/inhale-3-study-results-be-presented-during-90-minute-symposium

MNKD under $5

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-proceed-phase-1-nintedanib-dpi-mnkd-201-study-pulmonary

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-ind-clearance-us-fda-start-phase-3-study

$MNKD 4.65 NEWS https://twitter.com/health_stocks/status/1764971127560867938

well just got 6000 more shares thanks

MannKind Corp. said Tuesday it has entered a royalty agreement with Sagard Healthcare under which the latter will receive 1% of royalty sales of Tyvaso DPI inhalation powder for up to $200 million. United Therapeutics Corp. licensed Tyvaso DPI from MannKind in 2018 and started to market it in June 2022 as a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease following U.S. FDA approval. Under the terms of that deal, MannKind is entitled to a 10% royalty on sales of the treatment. Under its new agreement, Sagard will be entitled to royalty payments equal to 1% of net sales of Tyvaso DPI that are made between Oct. 1, 2023 and Dec. 31, 2042. MannKind will receive a $150 million upfront payment and $50 million if sales equal or exceed $1.9 billion by end-December 2026. If that milestone is not achieved, MannKind will get $45 million if the sales equal or exceed $2.3 billion by Sept. 30 of 2027. If neither milestone is achieved, MannKind will not receive the milestone payment and Sagard will not get any of the royalties payable in respect of sales that exceed $3.5 billion in any calendar year. MannKind’s stock fell 1% premarket and is down 31% over the last 12 months, while the S&P 500 has gained 24%.”

oh wow

“On June 26, 2023, MannKind Corporation (the “Company”) was informed that the contract manufacturer responsible for the production of clofazimine inhalation solution, the investigational product being developed by the Company as MNKD-101, experienced a fire in its manufacturing facility in Germany. As a result of this incident, the Company estimates that production of clinical supplies of MNKD-101 will be delayed by 3-6 months, which has the potential to impact the initiation of a Phase 2/3 clinical study of MNKD-101 planned for later in 2023. The Company is evaluating several mitigation strategies and will update the projected timing for this clinical study at a later date.”

Hopefully the clofazimine supply chain has some other nodes available outside of Germany.
https://investors.mannkindcorp.com/node/19231/html

https://imgur.com/a/lTiTEU4

“MannKind Corporation Common Stock is estimated to report earnings on 08/08/2023. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date.”

This is looking real sweet with solid growth and profit coming soon!

https://investors.mannkindcorp.com/node/19221/pdf

Considering the move into India with Cipla, and the addition of yet another highly qualified team member, it’s looking like some very good years ahead for MannKind.

https://investors.mannkindcorp.com/news-releases/news-release-details/dr-burkhard-blank-joins-mannkind-executive-vice-president

https://investors.mannkindcorp.com/news-releases/news-release-details/correction-mannkind-corporation-reports-2023-first-quarter

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by MannKind Corporation (Nasdaq: MKND), please note in the second table, titled "CONDENSED CONSOLIDATED BALANCE SHEETS", the right column header was incorrectly labeled as "March 31, 2022", when it should be labeled "December 31, 2022". The corrected release follows:

1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022
1Q 2023 Revenues associated with Tyvaso DPI of $23 million
1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million
$167 million of Cash, Cash Equivalents and Investments at March 31, 2023
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended March 31, 2023.

“Demand for Tyvaso DPI® has been very strong, which resulted in $23 million in revenues in the first quarter of 2023,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “I'm excited about our inhaled platform and orphan lung pipeline as we get ready to launch our Phase 2/3 inhaled clofazimine trial for patients in the second half of 2023.”

https://www.insideprecisionmedicine.com/topics/patient-care/therapeutics/respiratory-drugs/new-nanoparticles-carrying-mrna-can-perform-in-lung-gene-editing

Get a lungful of this!

Still long and strong

https://www.nasdaq.com/articles/blackrock-updates-holdings-in-mannkind-mnkd

https://www.fool.com/earnings/call-transcripts/2022/11/08/mannkind-corporation-mnkd-q3-2022-earnings-call-tr/

Well…plenty of other good things on the way!

Clofazimine, sold under the brand name Lamprene, is a medication used together with rifampicin and dapsone to treat leprosy. It is specifically used for multibacillary leprosy and erythema nodosum leprosum.

Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.

Dornase alfa is used to reduce the number of lung infections and to improve lung function in patients with cystic fibrosis.

Transforming growth factor-beta (TGFß) is a secreted cytokine, which intricately controls a plethora of physiological and pathological processes during development and carcinogenesis. TGFß exerts antiproliferative effects and functions as a tumor suppressor during early stages of tumorigenesis, whereas at later stages it functions as a tumor promoter aiding in metastatic progression through an autocrine TGFß loop. Intricate knowledge of TGFß signaling and its regulation are still evolving. In this review, we make an attempt to showcase the associated enigma of TGFß signaling in its dual functional role as tumor suppressor and metastatic promoter during early and late stages of carcinogenesis, respectively.

Technosphere® Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous insulins

The Afrezza with Basal Combination (ABC) Study demonstrated similar glucose control between the three treatment groups; data to be presented and published in 2023

Pretty good news!

“MannKind and United Therapeutics both surge the most in a year after the FDA approved their Tyvaso DPI product for lung disease.”

“Chief Executive Officer, Michael Castagna, PharmD, will ring the opening bell at the Nasdaq stock exchange on Monday, May 23, 2022 at 9:30 am ET at the Nasdaq MarketSite at Times Square.”

Will this also be a day of significant announcement(s)? ??

https://www.go-vgo.com/